MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma

Oncology

Volumn 57, Issue 3, 1999, Pages 242-252

  Vlaykova, Tatyana ^a   Talve, Lauri ^a   Hahka Kemppinen, Marjo ^b   Hernberg, Micaela ^b   Muhonen, Timo ^b   Franssila, Kaarle ^b   Collan, Yrjö ^a   Pyrhönen, Seppo ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

CD31; Metastatic melanoma; MIB 1; Proliferation; Vascularity

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CD31 ANTIGEN; DACARBAZINE; LOMUSTINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KI 67; PROTEINASE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DISSEMINATED CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TUMOR VASCULARIZATION;

ADULT; AGED; ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS; AUTOANTIGENS; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; KI-67 ANTIGEN; MALE; MELANOMA; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032840070     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012038     Document Type: Article

References (46)

1. Folkman J, Shing Y: Angiogenesis. J Biol Chem 1992;267:10931-10934.
2. Hahka-Kemppinen M, Muhonen T, Nordling S, Pyrhonen S: DNA flow cytometry and the outcome of chemoimmunotherapy in metastatic melanoma. Melanoma Res 1997;7:329-334.
3. Karlsson M, Jungnelius U, Aamdal S, Boeryd B, Carstensen J, Kagedal B, Westberg R, Wingren S: Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanoma. Int J Cancer 1996; 65:1-5.
4. Karlsson M, Boeryd B, Carstensen J, Kagedal B, Bratel AT, Wingren S: DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease. Br J Cancer 1993;67:134-138.
5. Muhonen T: Improving the prognostic value of DNA flow cytometry in metastatic melanoma by combining ploidy and S-phase fraction. Melanoma Res 1992;2:247-252.
6. Talve LA, Collan YU, Ekfors TO: Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin. J Cutan Pathol 1996;23:335-343.
7. Halpern AC, Schuchter LM: Prognostic models in melanoma. Semin Oncol 1997;24:S2-7.
8. Karjalainen J, Eskelinen M, Kosma VM, Lipponen P, Tuominen L, Alhava E: Clinical, histological and quantitative prognostic factors in cutaneous malignant melanoma. Anticancer Res 1992;12:1507-1511.
9. Fogt F, Vortmeyer AO, Tahan SR: Nucleolar organizer regions (AgNOR) and Ki-67 immunoreactivity in cutaneous melanocytic lesions. Am J Dermatopathol 1995;17:12-17.
10. Ronan SG, Farolan MJ, McDonald A, Manaligod JR, Das Gupta TK: Prognostic significance of nucleolar organizer regions (NORS) in malignant melanoma. J Cutan Pathol 1994;21: 494-499.
11. Evans AT, Blessing K, Orrell JM, Grant A: Mitotic indices, anti-PCNA immunostaining, and AgNORs in thick cutaneous melanomas displaying paradoxical behaviour. J Pathol 1992;168:15-22.
12. Ramsay JA, From L, Iscoe NA, Kahn HJ: MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 1995;105:22-26.
13. Reddy VB, Gattuso P, Aranha G, Carson HJ: Cell proliferation markers in predicting metastases in malignant melanoma. J Cutan Pathol 1995;22:248-251.
14. Vogt T, Zipperer KH, Vogt A, Holzel D, Landthaler M, Stolz W: p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology 1997;30:57-63.
15. Sparrow LE, English DR, Taran JM, Heenan PJ: Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. Am J Dermatopathol 1998;20:12-16.
16. Soyer HP: Ki-67 immunostaining in melanocytic skin tumors. Correlation with histologic parameters. J Cutan Pathol 1991;18:264-272.
17. Piérard GE, Piérard-Franchimont C: Stochastic relationship between the growth fraction and vascularity of thin malignant melanomas. Eur J Cancer 1997;33:1888-1892.
18. Boni R, Matt D, Voetmeyer A, Burg G, Zhuang Z: Chromosomal allele loss in primary cutaneous melanoma is heterogeneous and correlates with proliferation. J Invest Dermatol 1998;110:215-217.
19. Woosley JT, Dietrich DR: Prognostic significance of PCNA grade in malignant melanoma. J Cutan Pathol 1993;20:498-503.
20. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1994;133:1710-1715.
21. Lopez F, Belloc F, Lacombe F, Dumain P, Reiffers J, Bernard P, Boisseau MR: Modalities of synthesis of Ki-67 antigen during the stimulation of lymphocytes. Cytometry 1991;12:42-49.
22. Bruno S, Darzynkiewicz Z: Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif 1992;25:31-40.
23. Schwarting R: Little missed markers and Ki-67. Lab Invest 1993;68:597-599.
24. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363.
25. McCormick D, Chong H, Hobbs C, Datta C, Hall PA: Detection of the Ki-67 antigen in fixed and way-embedded sections with the monoclonal antibody MIB1. Histopathology 1993;22:355-360.
26. Boni R, Dogouglu A, Burg G, Muller B, Dummer R: MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 1996;35:416-418.
27. Stone CH, Lynch EF, Linden MD, Kubus JJ, Zarbo RJ: Immunocytochemical evaluation of proliferating cell nuclear antigen, Ki-67 (MIB-1), and p53 in predicting survival of primary and metastatic malignant melanomas. Appl Immunohistochem 1996;4:25-33.
28. Barnhill RL, Pierkorn MW, Cochran AJ, Flynn E, Karaoli T, Folkman J: Tumor vascularity, proliferation and apoptosis in human melanoma micrometastases and macrometastases. Arch Dermatol 1998;134:991-994.
29. Hernberg M, Turunen JP, von Boguslawsky K, Muhonen T, Pyrhönen S: Prognostic value of biomarkers in malignant melanoma. Melanoma Res 1998;8:283-291.
30. Folkman J: The role of angiogenesis in tumour growth. Semin Cancer Biol 1992;3:65-71.
31. Blood CH, Zetter BR: Tumor interactions with the vasculature: Angiogenesis and tumour metastasis. Biochim Biophys Acta 1990;1032:89-118.
32. Vlaykova T, Muhonen T, Hahka-Kemppinen M, Pyrhonen S, Jekunen A: Vascularity and prognosis of metastatic melanoma. Int J Cancer 1997;74:326-329.
33. Pyrhönen S, Hahka-Kemppinen M, Muhonen T: A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992;10:1919-1926.
34. Karlsson M, Boeryd B, Carstensen J, Franlund B, Gustafsson B, Kagedal B, Sun XF, Wingren S: Correlation of Ki-67 and PCNA to DNA ploidy, S-phase fraction and survival in uveal melanoma. Eur J Cancer 1996;32A:357-362.
35. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
36. Folkman J: Angiogenesis and breast cancer. J Clin Oncol 1994;12:441-443.
37. Gabbert H, Wagner R, Hohn P: The relation between tumor cell proliferation and vascularization in differentiated and undifferentiated colon carcinomas in the rat. Virchows Arch 1982;41:119-131.
38. Vermeulen PB, Verhoeven D, Hubens G, Van Marck E, Goovaerts G, Huyghe M, De Bruijn EA, Van Oosterom AT, Dirix LY: Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol 1995;6:59-64.
39. Porschen R, Classen S, Piontek M, Borchard F: Vascularization of carcinomas of the esophagus and its correlation with tumor proliferation. Cancer Res 1994;54:587-591.
40. Alcalde RE, Shintani S, Yoshihama Y, Matsumura T: Cell proliferation and tumor angiogenesis in oral squamous cell carcinoma. Anticancer Res 1995;15:1417-1422.
41. Vartanian RK, Weidner N: Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 1994;144:1188-1194.
42. Fox SB, Gatter KC, Bicknell R, Going JJ, Stanton P, Cooke TG, Harris AL: Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 1993; 53:4161-4163.
43. Smolle J, Soyer HP, Hofmann-Wellenhof R, Smolle-Juettner FM, Kerl H: Vascular architecture of melanocytic skin tumors. A quantitative immunohistochemical study using automated image analysis. Pathol Res Pract 1989; 185:740-745.
44. Halaban R: Growth factors and melanomas. Semin Oncol 1996;23:673-681.
45. Salven P, Heikkila P, Joensuu H: Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997; 76:930-934.
46. Shih IM, Herlyn M: Autocrine and paracrine roles for growth factors in melanoma. In Vivo 1994;8:113-123.